DCT

2:26-cv-09298

Knoa Pharma LLC v. Humanwell Pharma US Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-09298, D.N.J., 07/23/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey based on Defendants' systematic contacts with the state, including business registrations and intent to market the accused products there. The complaint also asserts that Defendants consented to venue in the district in a prior case.
  • Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market generic versions of the opioid pain medication HYSINGLA® ER constitutes an act of infringement of four U.S. patents covering tamper-resistant, controlled-release drug formulations.
  • Technical Context: The patents relate to abuse-deterrent formulations for opioid analgesics, a technology area of significant market and public health importance due to the risks of opioid misuse and abuse.
  • Key Procedural History: This action was filed under 35 U.S.C. § 271(e)(2) in response to a Paragraph IV certification notice letter sent by Defendant Humanwell, which triggers a statutory act of infringement. The complaint was filed within 45 days of receipt of the notice letter, initiating an automatic 30-month stay of FDA approval for the defendants' ANDA. The asserted patents are listed in the FDA's "Orange Book" for the branded drug HYSINGLA® ER.

Case Timeline

Date Event
2006-08-25 '416 Patent Priority Date
2010-12-22 '740 Patent Priority Date
2012-06-28 '740 Patent Application Published
2014-07-02 '740 Patent Allowed Claims Published
2014-07-14 '740 Patent Issue Fee Paid
2014-08-19 '740 Patent Issued
2014-11-21 '740 Patent Submitted for Orange Book Listing
2016-08-25 Application for '837 Patent Published
2017-05-11 Application for '416 Patent Published
2017-05-11 Application for '809 Patent Published
2017-08-07 '416 Patent Final Claims Published
2017-08-07 '809 Patent Final Claims Published
2017-08-10 '416 Patent Issue Fee Paid
2017-08-10 '809 Patent Issue Fee Paid
2017-09-26 '416 Patent Issued
2017-09-27 '416 Patent Submitted for Orange Book Listing
2017-10-03 '809 Patent Issued
2017-10-04 '809 Patent Submitted for Orange Book Listing
2017-11-08 '837 Patent Allowed Claims Published
2017-11-20 '837 Patent Issue Fee Paid
2018-01-23 '837 Patent Issued
2018-01-23 '837 Patent Submitted for Orange Book Listing
2026-06-09 Humanwell Sends Notice of Paragraph IV Certification
2026-07-23 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,808,740 - "Encased Tamper Resistant Controlled Release Dosage Forms," issued August 19, 2014

The Invention Explained

  • Problem Addressed: The patent addresses the abuse of controlled-release opioid formulations, where abusers tamper with the dosage form (e.g., by crushing or solvent extraction) to make the full dose of the opioid available for immediate, illicit use US 8,808,740, col. 1:21-30
  • The Patented Solution: The invention is a multi-layered, solid dosage form with a drug-containing core encased in a shell, both made from matrix materials. This "core-and-shell" structure is designed to be physically resistant to tampering, such as crushing, while providing a "substantially zero-order release" of the active agent over an extended period US 8,808,740, abstract US 8,808,740, col. 2:38-53
  • Technical Importance: This approach provided a physically robust dosage form that could deter common methods of tampering, a significant development in creating safer opioid pain medications.

Key Claims at a Glance

  • The complaint asserts independent claim 91 Compl. ¶ 42
  • The essential elements of claim 91 are:
    • A solid controlled release dosage form comprising a therapeutically effective amount of hydrocodone (or a salt) and a controlled release excipient.
    • The amount of hydrocodone released is proportional within 20% to elapsed time from 8 to 24 hours under specified in-vitro dissolution conditions.
    • The dosage form can be flattened to no more than 20% of its original thickness without breaking.
    • The drug release from a flattened dosage form at 0.5 hours deviates no more than 20% points from that of a non-flattened form.

U.S. Patent No. 9,872,837 - "Tamper Resistant Controlled Release Dosage Forms," issued January 23, 2018

The Invention Explained

  • Problem Addressed: The complaint does not provide the patent document for the '837 Patent, but its title and the context of the litigation suggest it addresses the same general problem of opioid abuse as the '740 Patent Compl. ¶ 31
  • The Patented Solution: Based on the language of claim 1, the invention is a solid dosage form where hydrocodone is dispersed in a matrix of high-molecular-weight polyethylene oxide. This dosage form is "cured" at a temperature of at least 60° C. for at least one minute, a process step intended to enhance its tamper-resistant properties Compl. ¶ 53
  • Technical Importance: The use of a specific polymer (polyethylene oxide) combined with a thermal curing step represents a particular manufacturing method to create a physically- and chemically-resistant opioid formulation.

Key Claims at a Glance

  • The complaint asserts independent claim 1 Compl. ¶ 53
  • The essential elements of claim 1 are:
    • A solid tamper resistant controlled release dosage form comprising hydrocodone (or a salt) dispersed in a matrix of polyethylene oxide with a specified average molecular weight.
    • The dosage form is cured at a temperature of at least 60° C. for at least 1 minute.
    • A specific multi-point in-vitro dissolution profile (e.g., <25% released at 2 hours, 10-30% at 4 hours).
    • The dosage form can be flattened to no more than 20% of its original thickness without breaking.
    • The drug release from a flattened dosage form at 0.5 hours deviates no more than 20% points from that of a non-flattened form.

Multi-Patent Capsule: U.S. Patent No. 9,770,416 - "Tamper Resistant Dosage Forms," issued September 26, 2017

  • Technology Synopsis: The '416 patent describes a pharmaceutical composition comprising an opioid active agent and high molecular weight polyethylene oxide (PEO) combined in a solid oral dosage form. The invention focuses on specific manufacturing process steps-including compression shaping, air curing with heated air, cooling, and hardening-and resulting physical properties, such as expansion upon curing and a specified hardness Compl. ¶ 66 These features are designed to create a tamper-resistant formulation.
  • Asserted Claims: The complaint asserts independent claim 1 Compl. ¶ 66
  • Accused Features: The complaint alleges that the Humanwell ANDA Products are a pharmaceutical composition that meets all the compositional, process, and property limitations of claim 1 of the '416 patent Compl. ¶ 67

Multi-Patent Capsule: U.S. Patent No. 9,775,809 - "Tamper Resistant Dosage Forms," issued October 3, 2017

  • Technology Synopsis: The '809 patent, similar to the '416 patent, describes a pharmaceutical composition with an opioid and high molecular weight PEO. It specifies manufacturing steps including compression shaping and air curing at a temperature above the PEO's softening point. The claims focus on the resulting composition's properties, including the percentage by weight of the PEO in the final dosage form Compl. ¶ 79
  • Asserted Claims: The complaint asserts independent claim 1 Compl. ¶ 79
  • Accused Features: The complaint alleges that the Humanwell ANDA Products are a pharmaceutical composition that meets all the limitations of claim 1 of the '809 patent, including its compositional makeup and the manufacturing process parameters Compl. ¶ 80

III. The Accused Instrumentality

Product Identification

  • The accused instrumentalities are the "Humanwell ANDA Products," which are hydrocodone bitartrate extended-release tablets in 20 mg, 30 mg, 40 mg, and 60 mg dosages Compl. ¶¶12 Compl. ¶ 38 The filing of ANDA No. 215216 itself is the act of infringement at issue Compl. ¶¶1 Compl. ¶ 46

Functionality and Market Context

  • The complaint alleges, on information and belief, that the Humanwell ANDA Products are generic versions of HYSINGLA® ER and therefore possess the same abuse-deterrent and controlled-release properties as the branded product Compl. ¶ 39 The allegations state the accused products are solid, controlled-release dosage forms containing hydrocodone and a controlled-release excipient, designed to be physically resistant to tampering and to exhibit specific in-vitro dissolution profiles that match the asserted claims Compl. ¶¶43 Compl. ¶ 54 Compl. ¶ 67 Compl. ¶ 80

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not contain a claim chart exhibit. The infringement theory is based on the allegation that because the Humanwell ANDA Products are generic versions of HYSINGLA® ER, for which the asserted patents are listed in the Orange Book, the generic products will necessarily have the properties and characteristics recited in the patent claims Compl. ¶ 39 The allegations for each patent largely track the language of the asserted independent claim.

U.S. Patent 8,808,740 Infringement Allegations

Claim Element (from Independent Claim 91) Alleged Infringing Functionality Complaint Citation Patent Citation
A solid controlled release dosage form comprising: a therapeutically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a controlled release excipient; The Humanwell ANDA Products are alleged to be a solid controlled release dosage form with a therapeutically effective amount of hydrocodone or a salt and a controlled release excipient. ¶43 col. 2:38-53
wherein the amount of hydrocodone or salt thereof released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution... The amount of hydrocodone released from the accused products is alleged to be proportional within 20% to elapsed time from 8 to 24 hours under the specified test conditions. ¶43 col. 2:44-53
the dosage form can be flattened without breaking, wherein the thickness of the dosage form after flattening corresponds to no more than about 20% of the thickness of the dosage form before flattening; The accused products can allegedly be flattened without breaking, with the thickness after flattening corresponding to no more than about 20% of the original thickness. ¶43 col. 5:2-12
the amount of hydrocodone or salt thereof released at 0.5 hour from a flattened dosage form deviates no more than about 20% points from a non-flattened dosage form... The drug release from the flattened accused products at 0.5 hours allegedly deviates no more than about 20% points from the release of a non-flattened dosage form. ¶43 col. 5:6-12

U.S. Patent 9,872,837 Infringement Allegations

The patent document for the '837 Patent was not provided with the complaint. Therefore, a claim chart with citations to the patent specification cannot be constructed. The complaint alleges infringement of claim 1 by tracking its language, asserting on information and belief that the Humanwell ANDA Products are a "solid tamper resistant controlled release dosage form" comprising hydrocodone in a polyethylene oxide matrix, which is "cured at a temperature of at least 60°C for at least 1 minute" and meets the specific dissolution and physical flattening properties recited in the claim Compl. ¶ 54

Identified Points of Contention

  • Scope Questions: The dispute may center on the construction of terms defining the physical and functional properties of the dosage form. For example, what constitutes "proportional within 20% to elapsed time" in claim 91 of the '740 patent? Does this require linearity across the entire 8-to-24-hour window, or only at the endpoints?
  • Technical Questions: A central technical question will be whether the Defendants' ANDA product, as formulated, actually exhibits the claimed properties. This will involve interpretation of the ANDA filing data and potentially new testing. For example, does the accused product in fact meet the specific multi-point dissolution profile of claim 1 of the '837 patent, and can it be "flattened without breaking" to the degree required by the claims?

V. Key Claim Terms for Construction

For U.S. Patent 8,808,740

  • The Term: "proportional within 20% to elapsed time"
  • Context and Importance: This term defines the controlled-release characteristic of the invention. The scope of this term is critical because if the accused product's release profile falls outside this range, it would not infringe. Practitioners may focus on this term as its construction will dictate the required level of linearity for the drug's release profile.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The claim language "from 8 to 24 hours" could be interpreted to mean that proportionality need only be met when comparing the 8-hour and 24-hour time points, not necessarily all points in between, which may broaden the range of acceptable release profiles US 8,808,740, claim 91
    • Evidence for a Narrower Interpretation: The specification's emphasis on achieving "substantially zero-order release" could support a narrower interpretation requiring a more consistent, linear release rate across the entire specified time interval, not just at the endpoints US 8,808,740, col. 1:17-20 The patent also provides specific examples of dissolution profiles that may be used to argue for a more constrained meaning US 8,808,740, FIGS. 1-3
  • The Term: "can be flattened without breaking"
  • Context and Importance: This term is a cornerstone of the tamper-resistance allegations. Its definition will determine the standard for the physical integrity of the dosage form under stress.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party could argue that "without breaking" means the tablet does not shatter into multiple pieces, allowing for the possibility of cracks or edge splits, thus encompassing a wider range of physical responses to force US 8,808,740, col. 26:48-50
    • Evidence for a Narrower Interpretation: The specification describes testing procedures using a "carver style bench press" and later, a "Texture Analyzer", which could be used to argue that the term should be limited to the specific types of forces and outcomes observed in those described tests US 8,808,740, col. 26:43-46 US 8,808,740, col. 27:5-31

For U.S. Patent 9,872,837

  • The complaint does not provide sufficient detail for analysis of key claim terms, as the patent document itself was not included.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that the commercial manufacture, use, sale, and importation of the Humanwell ANDA Products "with its proposed labeling" will infringe the asserted patents Compl. ¶ 51 Compl. ¶ 64 Compl. ¶ 77 Compl. ¶ 90 This allegation suggests a potential theory of induced infringement, where the product labeling would instruct users on an infringing use.
  • Willful Infringement: The complaint requests a finding of willful infringement Compl. prayer (f) The basis for this allegation is Defendants' alleged knowledge of the asserted patents prior to filing their ANDA. This knowledge is purportedly based on the patents' listing in the FDA's Orange Book and the receipt of the Paragraph IV notice letter, after which Defendants continued to seek approval for their generic products Compl. ¶¶44-45 Compl. ¶¶57-58 Compl. ¶¶70-71 Compl. ¶¶83-84

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of claim construction, specifically how the court defines the functional and physical properties of the claimed dosage forms. The case may turn on the precise meaning of terms such as "proportional within 20% to elapsed time" and "can be flattened without breaking," as these definitions will establish the specific, measurable benchmarks for infringement.
  • A central evidentiary question will be one of factual correspondence: does the formulation described in the Defendants' ANDA, which Plaintiffs have not yet seen, actually possess the physical and chemical properties required by the asserted claims? The dispute will likely evolve from the "information and belief" pleading stage to a battle of competing expert analyses of the ANDA data and physical tablet samples.
  • A key legal question will be the validity of the asserted claims. While the complaint alleges infringement, the Defendants' Paragraph IV certification asserts that the patents are invalid and/or not infringed Compl. ¶ 35 The litigation will therefore likely involve significant disputes over whether the claimed inventions were obvious or anticipated by the prior art at the time of invention.
Loading Complaint